Cargando…

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Detalles Bibliográficos
Autores principales:	Edelmann, Jennifer, Malcikova, Jitka, Riches, John C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9948015/ https://www.ncbi.nlm.nih.gov/pubmed/36845738 http://dx.doi.org/10.3389/fonc.2023.1106579

Ejemplares similares

Editorial: Biology and treatment of high-risk CLL
por: Tausch, Eugen, et al.
Publicado: (2023)

Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
por: Porrazzo, Marika, et al.
Publicado: (2020)

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
por: Shanafelt, Tait D., et al.
Publicado: (2022)

NF-kB and the CLL microenvironment
por: O’Donnell, Alice, et al.
Publicado: (2023)

NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia
por: Edelmann, Jennifer
Publicado: (2022)

Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
por: Slot, Matilde, et al.
Publicado: (2023)

Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2021)

P602: SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.
por: Kurucová, Terézia, et al.
Publicado: (2023)

Comparison of Immunotherapy, Chemotherapy, and Chemoimmunotherapy in Advanced Pulmonary Lymphoepithelioma-Like Carcinoma： A Retrospective Study
por: Xiao, Yi, et al.
Publicado: (2022)

Aberrant Promoter Hypomethylation in CLL: Does It Matter for Disease Development?
por: Upchurch, Garland Michael, et al.
Publicado: (2016)

Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

Emerging Therapies in CLL in the Era of Precision Medicine
por: Iyer, Prajish, et al.
Publicado: (2023)

Targeting ATM-deficient CLL through interference with DNA repair pathways
por: Knittel, Gero, et al.
Publicado: (2015)

Perioperative Outcomes of Video-Assisted Thoracoscopic Surgery Versus Open Thoracotomy After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC
por: Zhang, Baihua, et al.
Publicado: (2022)

Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
por: Zeng, Jun, et al.
Publicado: (2023)

Erratum: Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer
Publicado: (2023)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
por: Correia, Cristina, et al.
Publicado: (2023)

Non-Myeloablative Chemotherapy as Consolidation Strategy After High-Dose Methotrexate-Based Chemoimmunotherapy in Patients With Primary CNS Lymphoma: A Retrospective Single Center Study in China
por: Sun, Xuefei, et al.
Publicado: (2022)

Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis
por: Zhang, Baihua, et al.
Publicado: (2023)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

Pathologic complete response to chemoimmunotherapy of an advanced gastric cancer patient with high PD-L1 expression, dMMR, and unique gut microbiota composition: A case report
por: Jiang, Hongpeng, et al.
Publicado: (2023)

What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?
por: Gao, Wen, et al.
Publicado: (2020)

Characterizing Features of Human Circulating B Cells Carrying CLL-Like Stereotyped Immunoglobulin Rearrangements
por: Bagnara, Davide, et al.
Publicado: (2022)

Doing palliative care research on hematologic cancer patients: A realist synthesis of literature and experts’ opinion on what works, for whom and in what circumstances
por: Tanzi, Silvia, et al.
Publicado: (2023)

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL
por: Brazdilova, K, et al.
Publicado: (2018)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)

Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
por: Christofyllakis, Konstantinos, et al.
Publicado: (2021)

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies
por: Shatnyeva, Olga M., et al.
Publicado: (2015)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
por: Lovato, Ester, et al.
Publicado: (2023)

Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study
por: Jeon, Youngwoo, et al.
Publicado: (2023)

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis
por: Anpalakhan, Shobana, et al.
Publicado: (2023)

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy
por: Giunta, Emilio Francesco, et al.
Publicado: (2022)

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
por: Niemann, Carsten U., et al.
Publicado: (2022)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

B cell M-CLL clones retain selection against replacement mutations in their immunoglobulin gene framework regions
por: Neuman, Hadas, et al.
Publicado: (2023)

Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study
por: Gao, Yang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mdiq8e1e98qhilf041srk4tk3e